Dimerix Limited announced that its Phase 2a study of DMX-200 in patients with Focal Segmental Glomerulosclerosis (FSGS) is now fully recruited, with all 10 patients enrolled. The Phase 2a study is a double-blind, randomised, placebo-controlled, crossover study designed to evaluate the safety and preliminary signs of efficacy of DMX-200 in patients with FSGS who are receiving irbesartan. As previously announced, each participant in the study will receive 16 weeks DMX-200 and 16 weeks placebo, separated by a 6-week washout period. The first patient is expected to complete treatment in August 2019 and Dimerix will facilitate continued access to DMX-200 via their physician through the TGA Special Access Scheme. Clinicians at the study sites have reported no safety concerns to date, and Dimerix expects to report study results in the second quarter of calendar year 2020. Focal Segmental Glomerulosclerosis is a serious and rare disease that attacks the kidney's filtering units (glomeruli) causing scarring of the tissues, leading to permanent kidney damage and kidney failure. FSGS affects both children and adults. There are no treatments currently approved for the treatment of FSGS and thus there is a strong unmet medical need. Dimerix has received Orphan Drug Designation for DMX-200 in both the US and Europe for the treatment of FSGS.